AUTHOR=Koram Kwadwo Ansah , Walker Kathleen A. , Orizu Bonaventure , Marrero Idania , Boyer Jean , Yang ShuPing , Broderick Kate E. , Kusi Kwadwo Asamoah , Kyei-Baafour Eric , Ofori Ebenezer Addo , Pobee Abigail , Adu-Amankwah Susan , Amoakoh-Coleman Mary , Amoakoh Hannah Brown , Abuaku Benjamin , Badji Edem , Ntiri Michael , Quaye Lydia , Morrow Matthew P. , Sylvester Albert J. , Reuschel Emma L. , Gillespie Elisabeth , Liebowitz David , Humeau Laurent M. 

TITLE=Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults

JOURNAL=Frontiers in Immunology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1658549

DOI=10.3389/fimmu.2025.1658549

ISSN=1664-3224

ABSTRACT=BackgroundLassa fever (LF) is an acute viral hemorrhagic illness endemic to West Africa, with no licensed vaccines or targeted treatments available, highlighting a critical gap in global health preparedness. T cell-mediated immunity plays a central role in viral control and survival. Synthetic DNA vaccines offer a promising strategy to induce both humoral and cellular immunity against LF.MethodsA Phase 1b, randomized, double-blind, placebo-controlled trial was conducted to assess the safety, tolerability, and immunogenicity of INO-4500, a DNA vaccine encoding the Lassa virus (Josiah strain) glycoprotein precursor (GPC). A total of 220 healthy adults were randomized to receive either 1 mg or 2 mg of INO-4500 (intervention), or placebo, administered intradermally (ID) followed by electroporation (EP) at Day 0 and Week 4. Safety was evaluated through Week 48. Primary immunogenicity endpoints included humoral and cellular immune responses at multiple timepoints post-vaccination.ResultsINO-4500 was well tolerated, with no Grade 3 or higher treatment-emergent adverse events (TEAEs) deemed to be related to the intervention; 88.6% of all TEAEs were Grade 1. No cases of attributable hearing loss were reported. INO-4500 groups demonstrated statistically significant increases in Lassa virus GPC-specific binding antibodies at Weeks 6 and 12 compared to placebo, with the 2 mg group eliciting the strongest responses. T cell responses remained elevated above baseline through Week 48 in both INO-4500 groups, indicating durable cellular immunity.ConclusionsDNA vaccine INO-4500 was well tolerated and elicited durable humoral and cellular immune responses in healthy adults. These findings support further clinical development of INO-4500 as a potential preventive vaccine to reduce LF-associated morbidity and mortality in endemic regions.Clinical Trial Registrationhttps://clinicaltrials.gov, identifier NCT04093076